Biopharmaceutical company OncoSec Medical (OTC:ONCS) said Tuesday that a new "Method of Use" patent has been issued for the company's OMS ElectroOncology treatment platform by the Australia patent office.
The patent, titled “Method and Device for Treating Microscopic
Residual Tumors Remaining in Tissues Following Surgical Resection",
provides the company with the potential to expand its market
opportunities for minimally invasive and surgical procedures to treat
solid tumours - as an adjunct therapy to earlier-stage cancers.
Specifically, it allows the company's OMS technology to be used to
treat the margins of solid tumors following surgical resection.
One of the methods of treating solid tumours, which represent the
majority of all cancer incidences, is the surgical removal of the tumour
along with removal of the healthy tissue that surrounds the main
Removing the additional tissue is important as it ensures that
peripheral cancerous cells are also eliminated in order to prevent
recurrence. But the removal of healthy tissue can result in function
loss and have potentially detrimental cosmetic effects that may
jeopardize a patient's quality of life.
OncoSec's OMS ElectroChemotherapy is an investigational therapy that
is being evaluated to reduce the rate of cancer recurrence, without the
quality of life side effects that result from the removal of healthy
OncoSec uses its OMS electroporation delivery system that applies
short electric pulses to cells, causing the opening of pores in the cell
membrane, and allowing for the efficient and safe delivery of
immunotherapy or chemotherapy agents to treat a range of solid tumour
As a potential adjunct to surgery, the OMS ElectroChemotherapy
approach involves the removal of the tumor mass using a scalpel, without
removing any excess healthy tissue, followed by treatment with OMS
The therapy has been shown to selectively kill cancer cells that may
exist in the surrounding tissue, resulting in reduced recurrence rates.
"The issuance of this patent opens the possibility for improving
surgical outcomes in cancer therapy," said OncoSec's president and CEO,
"There is a tremendous unmet clinical need, especially for advanced
cancer where recurrence rates associated with surgery remain high."
"Treatment of margin tissue with our therapy potentially expands the
market for our product beyond those indications we are currently
pursuing for the use of the technology.
"We envision that surgical margins could be routinely treated with our therapy, providing increased benefit to patients."
OncoSec is currently focused on developing advanced-stage OMS
ElectroOncology therapies to treat solid tumors and metastatic disease.
The company recently announced it had entered into an exclusive
manufacturing agreement with DNA plasmid services business VGXI (VGXI)
for the production of its cancer immunotherapy.
The company said the exclusive agreement is significant as it uses
VGXI's patented DNA plasmid manufacturing process to produce the drug,
called interleukin-12 plasmid DNA (DNA IL-12), used in OncoSec's OMS
OMS ElectroImmunotherapy is currently being developed in phase II
studies for the treatment of three rare skin cancer indications -
metastatic melanoma, Merkel cell carcinoma and cutaneous T-cell
The locally administered and potentially systemic
ElectroImmunotherapy program uses the OMS electroporation system to
deliver the DNA-based immunotherapy, known as DNA IL-12.
The OMS electroporation system has proven to enhance cellular uptake,
effectively treating cancerous cells while sparing surrounding healthy
tissue cutting through the toxic side effects of current available
treatment options like chemotherapy and radiation.
Shares of OncoSec closed Monday at 18.1 cents.